The move strengthens Novartis’s foothold in rare muscle disorder treatments as it faces a looming patent cliff for key drugs like Entresto, Xolair and Cosentyx
Novartis to buy Avidity Biosciences for $12 billion
The move strengthens Novartis’s foothold in rare muscle disorder treatments as it faces a looming patent cliff for key drugs like Entresto, Xolair and Cosentyx